Why Gamida Cell Shares Are Falling Today
Why Gamida Cell Shares Are Falling Today
Gamida Cell Ltd. (NASDAQ:GMDA) shares are plunging in the morning session on Wednesday.
Gamida Cell Ltd.（納斯達克股票代碼：GMDA）股價在週三上午的交易中暴跌。
The company said it entered into a restructuring support agreement with certain funds managed by Highbridge Capital Management.
該公司表示，已與Highbridge Capital Management管理的某些基金簽訂了重組支持協議。
The transaction aims to offer Gamida Cell a long-term financial runway, aiding Omisirge (omidubicel-onlv) commercialization, via a voluntary Israeli restructuring proceeding.
該交易旨在通過以色列自願重組程序爲Gamida Cell提供長期的財務渠道，幫助Omisirge（omidubicel-onlv）商業化。
Highbridge will convert $75 million of its existing unsecured convertible senior note into equity in the company.
Highbridge將把其現有的7500萬美元無抵押可轉換優先票據轉換爲該公司的股權。
"Our search for strategic alternatives did not yield an actionable proposal from a partner who could address our financial challenges and support the ongoing commercialization of Omisirge," said Abbey Jenkins, President and Chief Executive Officer of Gamida Cell.
Gamida Cell總裁兼首席執行官Abbey Jenkins表示：“我們對戰略替代方案的探索未能從能夠應對我們的財務挑戰並支持Omisirge持續商業化的合作伙伴那裏得出切實可行的提案。”
"This restructuring transaction will enable Gamida Cell to remain a going concern and will support our ongoing efforts to make Omisirge available to more transplant centers and their patients."
“這項重組交易將使Gamida Cell保持持續經營狀態，並將支持我們爲向更多移植中心及其患者提供Omisirge所做的持續努力。”
The company will receive $30 million of new capital from Highbridge on the effective date of the restructuring.
在重組生效之日，該公司將從Highbridge獲得3000萬美元的新資本。
Gamida Cell will become a private company wholly owned by Highbridge, and the company's outstanding ordinary shares are expected to be canceled.
Gamida Cell將成爲一家由Highbridge全資擁有的私營公司，該公司的已發行普通股預計將被取消。
"Despite Gamida Cell's financial struggles, we believe in the potential of Omisirge to fulfill an important unmet need in stem cell transplant," said Jonathan Segal, Co-Chief Investment Officer at Highbridge Capital Management.
Highbridge Capital Management聯席首席投資官喬納森·西格爾表示：“儘管Gamida Cell陷入財務困境，但我們相信Omisirge有可能滿足幹細胞移植領域未得到滿足的重要需求。”
The company expects the transaction to close in the second quarter following approval by the Israeli court.
該公司預計，該交易將在以色列法院批准後於第二季度完成。
Gamida Cell reported net revenue of $1.8 million for the 12 months ending December 31, 2023, resulting from the delivery of 6 units of Omisirge.
Gamida Cell報告稱，截至2023年12月31日的12個月中，淨收入爲180萬美元，這要歸因於Omisirge的6個單位的交付。
The company reported a net loss per share of 57 cents for FY23, narrower than the net loss of $1.24 a year ago.
該公司報告稱，23財年每股淨虧損爲57美分，低於去年同期的1.24美元淨虧損。
As of December 31, 2023, Gamida Cell had total cash and equivalents of $46.6 million compared to $64.7 million as of December 31, 2022.
截至2023年12月31日，Gamida Cell的現金及等價物總額爲4,660萬美元，而截至2022年12月31日爲6,470萬美元。
Gamida Cell also announced certain organizational updates, under which it will implement a headcount reduction of 25%. In addition, as of March 31, 2024, Gamida Cell will finalize the wind-down of its Jerusalem office and consolidate all of its Israel operations in Kiryat Gat.
Gamida Cell還宣佈了某些組織更新，根據這些更新，它將裁員25％。此外，從2024年3月31日起，Gamida Cell將完成其耶路撒冷辦事處的關閉，並整合其在基里亞特加特的所有以色列業務。
Price Action: GMDA shares are trading lower by 82.5% to $0.06 on the last check Wednesday.
價格走勢：週三最後一次支票中，GMDA股價下跌82.5％，至0.06美元。
譯文內容由第三人軟體翻譯。